Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Zhejiang Huahai Approved for Generic HIV Drug

publication date: Jul 13, 2007
Nevirapine Covered by Patent until 2011 Zhejiang Huahai Pharmaceutical Co. Ltd. (SSH:600521) won tentative approval from the FDA in the US for its generic form of nevirapine, an HIV/AIDS drug. Tentative approval is given to drugs that are still protected by patent. The approval will become fully effective upon the expiration of the patent, held by Boehringer-Ingelheim, which markets the drug under the name Viramune. More details...


Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital